Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
1
50%
Ph not_applicable
1
50%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

recruiting150%
completed150%

Recent Activity

1 active trials
Showing 2 of 2
completedphase_2

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

NCT03311555
recruitingnot_applicable

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy

NCT03920033

Clinical Trials (2)

Showing 2 of 2 trials
NCT03311555Phase 2

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Completed
NCT03920033Not Applicable

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy

Recruiting

All 2 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
2